BNET Industries

Antares Pharma Inc.

(AIS) is in the Health Care Industry

Market Cap:$89.8M
Last Fiscal Year Sales:$7.8M
  • Public
  • US
Dow Jones Description

Antares Pharma, Inc. (?Antares? or the ?Company?) is a specialty drug delivery/pharmaceutical company utilizing its experience and expertise in drug delivery systems to enhance the performance of established and developing pharmaceuticals. The Company currently has three primary delivery platforms (1) transdermal gels, (2) fast-melt tablets, and (3) injection devices. These technologies are summarized and briefly described below. Technology Platforms [[Image Removed]] Transdermal Drug Delivery Antares? transdermal drug delivery platform is dedicated to developing gels that offer a cosmetically superior option to patches, while delivering medication efficiently with less potential for skin irritation and avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs. The Company?s gels consist of a hydro-alcoholic gel containing a combination of permeation enhancers to promote rapid drug absorption through the skin following application to the arms, shoulders, or abdomen.

President & Chief Executive Officer
Paul K Wotton PhD
Number of Employees 33
Contact Information

250 Phillips Blvd

Suite 290

Ewing, New Jersey 08618

www.antaresphar...

609-359-3020

NAICS Code Surgical and Medical Instrument Manufacturing: 339112

Recent Events

  • Ferring International to acquire assets of Antares Pharma

    11/13/09 - Merger / Acquisition - View Story

  • Antares Pharma Inks Licensing and Asset Purchase Pact with Ferring

    11/17/09 - Joint Venture / Alliance - View Story

  • Antares Pharma, Inc. ANTR Enters into License and Asset Purchase Agreements with Ferring; Majority of...

    11/11/09 - Joint Venture / Alliance - View Story

  • Antares Pharma Reports Third Quarter 2009 Financial and Operating Results

    11/09/09 - Financial Announcement - View Story

  • Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

    8/26/09 - Mgmt. Change Entering - CFO - View Story

  • Antares Pharma Q2 net loss narrows

    8/14/09 - Financial Announcement - View Story

  • BUYINS.NET: BXC, AIS, SENO, DISK, ROIA Expected To Be Lower Leading Up To Next Earnings...

    7/30/09 - Joint Venture / Alliance - View Story

  • Francis Collins to head NIH

    7/15/09 - Mgmt. Change Entering - CFO - View Story

  • Antares Pharma Promoted Robert Apple To EVP, CFO And President Of Parental Products Division -...

    7/08/09 - Mgmt. Change Entering - President - View Story

  • Antares Pharma Promotes Robert F. Apple, Dr. Kaushik Dave and Dr. Peter Sadowski

    7/08/09 - Mgmt. Change Entering - CFO - View Story

News & Analysis

antares pharma inc. and company - All News and Analysis

Decision Makers

Name (plus bio) Position
Paul K Wotton PhD President & Chief Executive Officer
Robert F Apple Senior Vice President and Cfo
James E Hattersley Vice President, Corporate Business Development
Lawrence M Christian Vice President, Finance
Peter Sadowski Vice President, Devices Group
Michael L Kasprick Executive Director, Corporate Business Development
Dario Carrara Director, Formulations Group

Board of Directors

Name (plus bio) Position
Leonard S Jacob Chairman
Jacques Gonella Board of Directors

Organization Position Status
Antares Pharma, Inc. President & Chief Executive Officer Current
Genaera Corporation Board of Directors Current
Topigen Pharmaceuticals Inc President and Chief Executive Officer Former
Antares Real Estate Services President Former
Antares Real Estate Services Chief Operating Officer Former
Antares Pharma, Inc. Chief Operating Officer Former
Skyepharma, Inc. Head of Global Business Development Former
SkyePharma PLC Head of Global Business Development Former
Abbott Laboratories Former
Penwest Pharmaceuticals, Co. Former
University of Nottingham PhD In Pharmaceutical Science Former
Kingston Business School MBA Former
University of London Bachelor in Pharmacy degree Former

Organization Position Status
Antares Pharma, Inc. Senior Vice President and Cfo Current

Organization Position Status
Antares Pharma, Inc. Vice President, Corporate Business Development Current

Organization Position Status
Antares Pharma, Inc. Vice President, Finance Current

Organization Position Status
Antares Pharma, Inc. Vice President, Devices Group Current

Organization Position Status
Antares Pharma, Inc. Executive Director, Corporate Business Development Current

Organization Position Status
Antares Pharma, Inc. Director, Formulations Group Current

Organization Position Status
Pharmaderm Director and Chairman of the Nominating and Corporate Governance Committee Current
Antares Pharma, Inc. Chairman Current
Life Science Advisors, LLC Chairman Current
The Colon Cancer Alliance Board Member Current
The Recording Company Director Current
Jacob Internet Fund Director Current
Macromed, Inc. Director Current
Glyconix Corp Board of Directors Current
Quiqmeds, Inc. Board of Directors Current
The Colon Cancer Alliance Chairman of the Board of Directors and Chief Executive Officer Former
Genaera Corporation Chief Operating Officer Former
SmithKline Beecham Corporation Worldwide Vice President Former
Genaera Corporation Co-Founder Former
Temple University Ph.D. In Pharmacology Former
Medical College of Pennsylvania M.D. Former
GlaxoSmithKline Plc member Former

Organization Position Status
Antares Pharma, Inc. Board of Directors Current
Permatech, Inc. Chairman Former
Antares Pharma, Inc. Chairman Former

Executive News

  • Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

    Pharmaceutical Technology - 8/26/09 - View Story

  • Antares Pharma Announces Launch of Tjet Needle-Free Injector

    Business Wire via MSN Money - 8/25/09 - View Story

  • Antares Pharma Announces Launch of Tjet Needle-Free Injector System by Marketing Partner Teva

    Business Wire - 8/25/09 - View Story

  • Antares Pharma Q2 net loss narrows

    TradingMarkets - 8/14/09 - View Story

  • Antares Pharma Reports Second Quarter 2009 Financial and

    Business Wire via MSN Money - 8/13/09 - View Story

  • Antares Pharma Reports Second Quarter 2009 Financial and Operating Results

    RBC Dain Raushcer - 8/13/09 - View Story

  • Antares Pharma Welcomes Eamonn P. Hobbs to Board of Directors

    Business Wire - 8/12/09 - View Story

advertisement
     AIS $1.10 +0.02 (1.85% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 493,465
Shares Outstanding 81.71M
Market Cap 89.9M
Year High 1.31
Year Low 0.29
Earnings Per Share -0.15
P/E Ratio -7.33
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Presented by American Express